Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis - 12/08/11
Reprint requests: Steven R. Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard Winston-Salem, NC 27157-1071.Winston-Salem, North Carolina, and Columbus, Ohio
Abstract |
Background |
Atopic dermatitis is a common problem for which topical agents are the primary treatment. When topical medications fail, further therapy may include systemic agents with the potential for greater toxicity. Adherence to topical treatment of atopic dermatitis has not been well characterized. Poor adherence to topical medication could account for failure of topical therapy.
Purpose |
To determine adherence to topical treatment in patients with atopic dermatitis.
Methods |
Thirty-seven children were given 0.1% triamcinolone ointment and were counseled to use it twice daily. They were told to return in 4 weeks, at which time they were told to continue treatment for another 4 weeks. Electronic monitors were used to measure adherence over the entire 8 week study. Patients were not informed of the compliance monitoring until the end of the study.
Results |
Twenty-six patients completed 8 weeks of treatment. Mean adherence from the baseline to the end of the study was 32%. Adherence was higher on or near office visit days and subsequently decreased rapidly.
Limitations |
This study was limited by the large number of subjects who failed to return for follow-up appointments or withdrew from the study.
Conclusions |
Adherence to topical medications is very poor in a clinic population of children with atopic dermatitis. Office visits are one means to increase adherence. If adherence to topical treatment can be improved, exposure to more costly and potentially toxic systemic agents may be avoidable.
Le texte complet de cet article est disponible en PDF.Abbreviations used : EASI, IGA, MEMS, SAS
Plan
| Funding sources: None. Disclosure: The Center for Dermatology Research is supported by an educational grant from Galderma Laboratories, L.P. The authors have no conflicts of interest to disclose. |
Vol 56 - N° 2
P. 211-216 - février 2007 Retour au numéro
Article précédent
- Pityriasis lichenoides in childhood: A retrospective review of 124 patients
- Sibel Ersoy-Evans, M. Fernanda Greco, Anthony J. Mancini, Nuket Subaşı, Amy S. Paller
- Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab
- Akmal S. Hassan, Ursula Kaelin, Lasse Roger Braathen, Nikhil Yawalkar
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?